KDR and renal cell carcinoma: Anti-angiogenic tyrosine kinase inhibitors (TKIs) have been approved as first-line treatments in RCC, with their proposed mechanism of action to be disruption of signaling in the VEGF/VEGFR2 pathway (4–6).